文献速递乳腺癌

9种乳腺癌易感基因致病性胚系变异相关肿瘤的病理学特征

Pathology of Tumors Associated With Pathogenic Germline Variants in 9 Breast Cancer Susceptibility Genes.
PubMed 文献 · JAMA Oncol · 2022-03-17

BRIDGES多中心国际病例对照研究纳入42680例乳腺癌患者和46387名对照,分析ATM、BARD1、BRCA1、BRCA2、CHEK2、PALB2、RAD51C、RAD51D和TP53致病性胚系变异与乳腺癌分子亚型及病理特征的关系。结果显示不同基因相关肿瘤的内在亚型分布差异显著,多与三阴性及/或高级别肿瘤相关,且在多数基因和亚型中比值比随年龄增长而下降。

要点

  • RAD51C、RAD51D和BARD1变异主要与三阴性乳腺癌相关,OR分别为6.19、6.19和10.05。
  • BRCA1变异与所有亚型风险升高相关,三阴性亚型OR最高为55.32。
  • 9个基因合计与40岁及以下女性中27.3%的三阴性肿瘤相关。

核心结论

  • 9种乳腺癌风险基因的致病变异相关病理差异显著,但总体与三阴性和/或高级别疾病相关。
  • 了解各基因相关的年龄和肿瘤亚型分布可能有助于基因panel检测指南、风险预测、变异分类及指导靶向筛查策略。

研究设计与样本

  • BRIDGES研究为多中心国际病例对照分析,纳入42680例患者和46387名对照,为18至79岁女性,不依赖家族史从38项研究中独立采样。
  • 研究于1991年至2016年间开展,测序和分析于2016年至2021年间进行。
  • 暴露因素为ATM、BARD1、BRCA1、BRCA2、CHEK2、PALB2、RAD51C、RAD51D和TP53中的蛋白截短变异和可能致病的错义变异。

主要发现

  • 对照访谈时平均(SD)年龄为55.1(11.9)岁,病例诊断时平均(SD)年龄为55.8(10.6)岁;所有参与者均为欧洲或东亚裔。
  • RAD51C、RAD51D和BARD1变异主要与三阴性病变相关,OR分别为6.19(95%CI,3.17-12.12)、6.19(95%CI,2.99-12.79)和10.05(95%CI,5.27-19.19)。
  • CHEK2变异与除三阴性外的所有亚型相关,OR范围为2.21-3.17。
  • ATM变异与激素受体(HR)+ERBB2-高级别亚型关联最强,OR为4.99(95%CI,3.68-6.76)。
  • BRCA1与所有亚型风险升高相关,OR差异大,三阴性最高为55.32(95%CI,40.51-75.55);BRCA2和PALB2变异亦与三阴性相关;TP53变异与HR+ERBB2+和HR-ERBB2+亚型关联最强。

关键数值与推荐

  • 致病性变异携带者的肿瘤级别更高。
  • 对多数基因和亚型,OR随年龄增长而下降。
  • 9个基因合计与40岁及以下女性中27.3%的三阴性肿瘤相关。

临床怎么用

  • 原文未据此给出推荐。
  • 作者认为,了解各乳腺癌基因相关的年龄和肿瘤亚型分布可能有助于基因panel检测指南、风险预测和变异分类,并指导靶向筛查策略。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Rare germline genetic variants in several genes are associated with increased breast cancer (BC) risk, but their precise contributions to different disease subtypes are unclear. This information is relevant to guidelines for gene panel testing and risk prediction. OBJECTIVE: To characterize tumors associated with BC susceptibility genes in large-scale population- or hospital-based studies. DESIGN, SETTING, AND PARTICIPANTS: The multicenter, international case-control analysis of the BRIDGES study included 42 680 patients and 46 387 control participants, comprising women aged 18 to 79 years who were sampled independently of family history from 38 studies. Studies were conducted between 1991 and 2016. Sequencing and analysis took place between 2016 and 2021. EXPOSURES: Protein-truncating variants and likely pathogenic missense variants in ATM, BARD1, BRCA1, BRCA2, CHEK2, PALB2, RAD51C, RAD51D, and TP53. MAIN OUTCOMES AND MEASURES: The intrinsic-like BC subtypes as defined by estrogen receptor, progesterone receptor, and ERBB2 (formerly known as HER2) status, and tumor grade; morphology; size; stage; lymph node involvement; subtype-specific odds ratios (ORs) for carrying protein-truncating variants and pathogenic missense variants in the 9 BC susceptibility genes. RESULTS: The mean (SD) ages at interview (control participants) and diagnosis (cases) were 55.1 (11.9) and 55.8 (10.6) years, respectively; all participants were of European or East Asian ethnicity. There was substantial heterogeneity in the distribution of intrinsic subtypes by gene. RAD51C, RAD51D, and BARD1 variants were associated mainly with triple-negative disease (OR, 6.19 [95% CI, 3.17-12.12]; OR, 6.19 [95% CI, 2.99-12.79]; and OR, 10.05 [95% CI, 5.27-19.19], respectively). CHEK2 variants were associated with all subtypes (with ORs ranging from 2.21-3.17) except for triple-negative disease. For ATM variants, the association was strongest for the hormone receptor (HR)+ERBB2- high-grade subtype (OR, 4.99; 95% CI, 3.68-6.76). BRCA1 was associated with increased risk of all subtypes, but the ORs varied widely, being highest for triple-negative disease (OR, 55.32; 95% CI, 40.51-75.55). BRCA2 and PALB2 variants were also associated with triple-negative disease. TP53 variants were most strongly associated with HR+ERBB2+ and HR-ERBB2+ subtypes. Tumors occurring in pathogenic variant carriers were of higher grade. For most genes and subtypes, a decline in ORs was observed with increasing age. Together, the 9 genes were associated with 27.3% of all triple-negative tumors in women 40 years or younger. CONCLUSIONS AND RELEVANCE: The results of this case-control study suggest that variants in the 9 BC risk genes differ substantially in their associated pathology but are generally associated with triple-negative and/or high-grade disease. Knowing the age and tumor subtype distributions associated with individual BC genes can potentially aid guidelines for gene panel testing, risk prediction, and variant classification and guide targeted screening strategies.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Mavaddat N, Dorling L, Carvalho S, et al. Pathology of Tumors Associated With Pathogenic Germline Variants in 9 Breast Cancer Susceptibility Genes. JAMA Oncol. 2022. PMID: 35084436. doi:10.1001/jamaoncol.2021.6744

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。